PR Interval Prognostic of Cardiac Resynchronization Tx Outcome

Share this content:
PR Interval Prognostic of Cardiac Resynchronization Tx Outcome
PR Interval Prognostic of Cardiac Resynchronization Tx Outcome

WEDNESDAY, Feb. 15, 2017 (HealthDay News) -- For patients with advanced systolic heart failure, the impact of cardiac resynchronization therapy with defibrillation (CRT-D) varies according to PR interval, according to research published in the February issue of the Journal of Cardiovascular Electrophysiology.

Jeffrey Lin, M.D., from the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues stratified 308 patients enrolled in the optimal pharmacologic therapy (OPT) and 595 patients in the CRT-D arms of the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure trial according to normal (≤230 ms) or prolonged (>230 ms) PR interval.

The researchers found that, compared with OPT, CRT-D treatment correlated with reduced hospitalization or all-cause mortality (ACM) and ACM (P = 0.002 and 0.003, respectively). In patients with longer baseline PR intervals, CRT-D was increasingly more effective in reducing ACM hazard (P = 0.002), irrespective of left bundle branch block (LBBB) status. ACM was reduced with CRT-D versus OPT (P = 0.001) in the prolonged baseline PR interval subgroup, with little evidence of a reduction in ACM in the normal PR subgroup (P = 0.07).

"In patients with advanced systolic heart failure, wide QRS complexes, and prolonged PR intervals, restoration of atrioventricular mechanical coupling with CRT-D may improve survival regardless of LBBB status," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »